On July 10th, Gelonhui reported that Pacific Shuanglin Bio-Pharmacy (000403.SZ) announced its performance forecast for the first half of 2024. The net income attributable to the shareholders of the company is expected to be between CNY 0.315 billion and CNY 0.344 billion, an increase of 120% to 140% from the same period last year. The net income, after deducting the non-recurring gains and losses, is expected to be between CNY 0.281 billion and CNY 0.313 billion, an increase of 170% to 200% from the same period last year. The EPS is expected to be between CNY 0.4309 per share and CNY 0.4700 per share.
The main reason for the increase in performance is because the sales demand in the blood products market is strong, the year-on-year growth of raw material plasma collection is good, and the company's salable product quantity and sales volume are expected to increase in the first half of 2024, resulting in an increase of the main business income compared to the same period last year.